Medtronicの空売り状況は、投資家がMedtronicの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Medtronic (NYSE:MDT) 株価情報, 空売り情報

Medtronic

One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.

Medtronic PLC

Measurable Data Token - United States Dollar

MEDIA TECHS INC by Media Technologies Inc.

Media Technologies Inc

MEDIA TEK INC by Media Tek Inc.

MANDATUM OYJ U/ADR by MANDATUM OYJ

MEDITERRANEAN TOWERS LTD by Mediterranean Towers LTD

Mediterranean Towers Ltd

Bank of America Securities connected with Intuitive Surgical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) on reprocessing &#8220;noise&#8221; in the market.
Analyst Travis Steed highlighted that reprocessing is not new to Intuitive, even though it might seem like new news to some investors.
What Happened: For the unversed, in March this year, Restore Robotics received 510(k) <a target="_blank" href="https://www.prnewswire.com/news-releases/restore-robotics-receives-fda-510k-clearance-for-remanufacturing-da-vinci-xi-8mm-monopolar-curved-scissors-302409135.html" rel="noreferrer noopener">clearance</a> from the U.S. Food and Drug Administration (FDA) for remanufacturing Intuitive Surgical&#8217;s Da Vinci Xi Monopolar Scissors as of March 11, 2025, through its subsidiary Iconocare Health.
In a statement, Restore Robotics said it is offering hospitals and surgery centers a cost-effective and sustainable alternative to purchasing instruments from the original manufacturer.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44966347/analysts-remain-bullish-on-intuitive-surgical-despite-macro-uncertainty" rel="noreferrer noopener">Analysts Remain Bullish On Intuitive Surgical Despite Macro Uncertainty</a>
In May, Restore Robotics announced that Dr. Eugene Dickens at Hillcrest Medical Center in Tulsa, Oklahoma, conducted the first in-human use of a remanufactured da Vinci&nbsp; Xi robotic instrument on a patient using the newest model robotic surgical system, the da Vinci 5.
In addition, Panama City Surgery Center performed the first in-human use on a da Vinci Xi, which is the workhorse of the da Vinci robotics surgical systems.
Restore Robotics <a target="_blank" href="https://www.prnewswire.com/news-releases/first-in-human-use-of-remanufactured-da-vinci-xi-robotic-instruments-302467048.html" rel="noreferrer noopener">said</a> it is working on getting clearances for other da Vinci robotic instruments.
Why It Matters: Deutsche Bank downgraded Intuitive Surgical from Hold to Sell on Monday, lowering the price forecast from $515 to $440.
BofA analyst Steed noted that some companies have offered services for Intuitive&#8217;s surgical robots and sold remanufactured instruments for years.
Intuitive does not ban third-party remanufactured instruments as long as they have received 510(k) clearance or a similar approval from the FDA.
The company also clarified that it won&#8217;t cancel service contracts, stop doing business, or consider it a contract violation if a U.S. customer uses these FDA-cleared, third-party instruments.
On Friday, BofA maintained the Buy rating with a <a href="https://www.benzinga.com/quote/ISRG/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast of $650</a> and sees continued potential upside to Street estimates.
&#8220;One thing that gives us some comfort that reprocessing will only be a small share of the market over the long term is reprocessing today is only a small low single-digit percent headwind on Medtronic Plc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) global surgical business and its isolated mostly in its US vessel sealing and dissection product lines.&#8221;
BofA thinks reprocessing in robotic instruments will only be a small share of customers and tries to innovate accordingly.
On Wednesday, an analyst note by William Blair on this development suggested that hospitals investing millions of dollars in a robotics program will take a pause at operating outside the Intuitive Surgical ecosystem.
The high cost and critical nature of these surgical investments make operating outside of Intuitive&#8217;s established and supported ecosystem a significant risk for healthcare providers, the note added.
Currently, the threat is considered minimal as only one third-party instrument has received FDA clearance, and Intuitive does not offer direct support for such products. While the analyst acknowledged this as a potential long-term risk to watch, the immediate impact is expected to be limited.
Therefore, despite negative headlines that could cause short-term volatility for the premium-valued stock (cited at 57 times 2026 EPS), analyst Brandon Vazquez of William Blair maintains an Outperform rating on the company.
Price Action: ISRG stock is trading lower by 0.72% to $516.70&nbsp;at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45540768/medtronic-beats-q4-forecasts-hikes-dividend-plans-diabetes-spinoff" target="_blank" rel="noreferrer noopener">Medtronic Beats Q4 Forecasts, Hikes Dividend, Plans Diabetes Spinoff</a></li>
</ul>
Image via Shutterstock

Analyst Color

Large Cap

News

Health Care

Analyst Ratings

General

ISRG

Limited Impact On Intuitive Surgical From Reprocessed Robotic Instruments: Analyst

Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) announced on May 21 its plans to separate its Diabetes business into a separate, publicly traded company. The separation will occur via a two step transaction &#8211; an initial minority IPO carve-out followed by a split-off of the remaining stake. The separation will be tax-free for the shareholders and is expected to be completed in the next 18 months.
The separation comes as Medtronic focuses on higher-margin, faster-growing businesses such as pulsed field ablation and renal denervation. The Diabetes segment, which contributed $2.75 billion or 8% of FY2025 revenue, has lagged behind peers in growth and profitability, facing stiff competition from companies like Dexcom (DXCM), Abbott (ABT), and Tandem Diabetes Care (TNDM).
Strategic Rationale
Diabetes business is predominantly B2C, while Medtronic operates mainly in the B2B space. This implies that both businesses sell different types of products to different types of customers. As such, there are limited synergies between the businesses which justify the argument for separation.
With the spin-off, the diabetes unit, dubbed "SpinCo," will gain operational autonomy and flexibility to scale up R&amp;D and commercial efforts.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="605" height="161" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/13100846/Details.png" alt="" class="wp-image-14339" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/13100846/Details.png 605w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/13100846/Details-300x80.png 300w" sizes="(max-width: 605px) 100vw, 605px" /></figure>
Valuation Despite past underperformance, the Diabetes business is showing signs of a turnaround, growing 10.7% year-over-year in FY2025. GSBR Research estimates the standalone DiabetesCo could be valued between $8 billion and $11 billion, depending on market sentiment and growth execution.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="457" height="143" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/13100917/Spin.png" alt="" class="wp-image-14340" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/13100917/Spin.png 457w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/13100917/Spin-300x94.png 300w" sizes="(max-width: 457px) 100vw, 457px" /></figure>
Medtronic's core business &#8211; excluding Diabetes &#8211; generated nearly $31 billion in FY2025 revenue, and are characterized by higher margins. Post spin, the portfolio will become even more focused on high margin growth markets such as pulse (PFA) and renal denervation. This is expected to expand operating margins by 100 bps.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="500" height="201" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/13100928/MedexSpin.png" alt="" class="wp-image-14341" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/13100928/MedexSpin.png 500w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/13100928/MedexSpin-300x121.png 300w" sizes="(max-width: 500px) 100vw, 500px" /></figure>
Bottom line: The diabetes spin-off will unlock value for both Medtronic and the SpinCo. Medtronic (ex-Diabetes) will become a higher-margin company. The spin-off could also trigger a re-rating of Medtronic shares, as investors reassess its streamlined profile. Meanwhile, the diabetes business will gain greater autonomy and flexibility to aggressively invest in its innovation pipeline. The Diabetes business could trade in the range of 3-4x P/S multiple and as such could potentially be valued between $8-$11 billion.

Biotech

Long Ideas

IPOs

Opinion

Trading Ideas

Medtronic Is Separating Its Diabetes Business - Good News For Investors

Medtronic Announces MiniMed As Name For Planned New Diabetes Company Following Intended Separation

Analysts' ratings for Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Medtronic and provided 12-month price targets. The average target is $95.25, accompanied by a high estimate of $101.00 and a low estimate of $90.00. Observing a downward trend, the current average is 2.81% lower than the prior average price target of $98.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1749211243_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Medtronic among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$98.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$101.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$92.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$90.00</td>
<td>$93.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Medtronic. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Medtronic compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Medtronic's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MDT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Medtronic analyst ratings.</a>
<h2>Get to Know Medtronic Better</h2>
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
<h3>Financial Insights: Medtronic</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Medtronic's revenue growth over a period of 3M has been noteworthy. As of 30 April, 2025, the company achieved a revenue growth rate of approximately 7.66%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Medtronic's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 11.84%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Medtronic's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.17% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Medtronic's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.16%, the company showcases efficient use of assets and strong financial health.
Debt Management: Medtronic's debt-to-equity ratio is below the industry average. With a ratio of 0.59, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Medtronic: 4 Analysts Share Their Views

Needham analyst Mike Matson reiterates Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) from Hold to Hold.

Reiteration

Needham Reiterates Hold on Medtronicto Hold

<a href="https://www.fda.gov/medical-devices/medical-device-recalls/flexible-tracheostomy-tube-recall-medtronic-removes-shiley-adult-flexible-tracheostomy-tube#:~:text=Medtronic%20and%20its%20subsidiary%20Covidien,the%20securement%20flange%20becomes%20disconnected" title="https://www.fda.gov/medical-devices/medical-device-recalls/flexible-tracheostomy-tube-recall-medtronic-removes-shiley-adult-flexible-tracheostomy-tube#:~:text=Medtronic%20and%20its%20subsidiary%20Covidien,the%20securement%20flange%20becomes%20disconnected">https://www.fda.gov/medical-devices/medical-device-recalls/flexible-tracheostomy-tube-recall-medtronic-removes-shiley-adult-flexible-tracheostomy-tube#:~:text=Medtronic%20and%20its%20subsidiary%20Covidien,the%20securement%20flange%20becomes%20disconnected</a>.

'Flexible Tracheostomy Tube Recall: Medtronic Removes Shiley Adult Flexible Tracheostomy Tube with TaperGuard Cuff Reusable Inner Cannula Due to Risk for Disconnection of the Flange from the Device Cannula' - FDA

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$55.00</td>
<td>$71.1K</td>
<td>2.1K</td>
<td>1.3K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/06/25</td>
<td>$25.00</td>
<td>$68.0K</td>
<td>2.2K</td>
<td>1.0K</td>
</tr>
<tr>
<td>GILD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/06/25</td>
<td>$100.00</td>
<td>$44.0K</td>
<td>1.1K</td>
<td>960</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$630.00</td>
<td>$119.6K</td>
<td>6</td>
<td>705</td>
</tr>
<tr>
<td>VEEV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$210.00</td>
<td>$65.7K</td>
<td>534</td>
<td>589</td>
</tr>
<tr>
<td>NVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$115.00</td>
<td>$28.0K</td>
<td>1.8K</td>
<td>379</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$80.00</td>
<td>$42.5K</td>
<td>883</td>
<td>372</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$295.00</td>
<td>$40.2K</td>
<td>985</td>
<td>344</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$195.00</td>
<td>$25.8K</td>
<td>5.0K</td>
<td>319</td>
</tr>
<tr>
<td>COR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$280.00</td>
<td>$36.4K</td>
<td>762</td>
<td>200</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we notice a put option sweep that happens to be bearish, expiring in 51 day(s) on July 18, 2025. This event was a transfer of 89 contract(s) at a $55.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $71.1K, with a price of $799.0 per contract. There were 2196 open contracts at this strike prior to today, and today 1320 contract(s) were bought and sold. 
• For MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we notice a put option sweep that happens to be bearish, expiring in 9 day(s) on June 6, 2025. This event was a transfer of 1000 contract(s) at a $25.00 strike. This particular put needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $68.0K, with a price of $68.0 per contract. There were 2289 open contracts at this strike prior to today, and today 1083 contract(s) were bought and sold. 
• For GILD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), we notice a put option trade that happens to be bearish, expiring in 9 day(s) on June 6, 2025. This event was a transfer of 958 contract(s) at a $100.00 strike. The total cost received by the writing party (or parties) was $44.0K, with a price of $46.0 per contract. There were 1139 open contracts at this strike prior to today, and today 960 contract(s) were bought and sold. 
• Regarding REGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>), we observe a call option trade with neutral sentiment. It expires in 51 day(s) on July 18, 2025. Parties traded 46 contract(s) at a $630.00 strike. The total cost received by the writing party (or parties) was $119.6K, with a price of $2600.0 per contract. There were 6 open contracts at this strike prior to today, and today 705 contract(s) were bought and sold. 
• Regarding VEEV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>), we observe a put option sweep with bearish sentiment. It expires in 23 day(s) on June 20, 2025. Parties traded 212 contract(s) at a $210.00 strike. This particular put needed to be split into 45 different trades to become filled. The total cost received by the writing party (or parties) was $65.7K, with a price of $310.0 per contract. There were 534 open contracts at this strike prior to today, and today 589 contract(s) were bought and sold. 
• For NVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>), we notice a call option sweep that happens to be bullish, expiring in 23 day(s) on June 20, 2025. This event was a transfer of 224 contract(s) at a $115.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $28.0K, with a price of $125.0 per contract. There were 1879 open contracts at this strike prior to today, and today 379 contract(s) were bought and sold. 
• For MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we notice a call option trade that happens to be bearish, expiring in 79 day(s) on August 15, 2025. This event was a transfer of 100 contract(s) at a $80.00 strike. The total cost received by the writing party (or parties) was $42.5K, with a price of $425.0 per contract. There were 883 open contracts at this strike prior to today, and today 372 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a call option trade with bullish sentiment. It expires in 23 day(s) on June 20, 2025. Parties traded 134 contract(s) at a $295.00 strike. The total cost received by the writing party (or parties) was $40.2K, with a price of $300.0 per contract. There were 985 open contracts at this strike prior to today, and today 344 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a call option trade that happens to be bullish, expiring in 23 day(s) on June 20, 2025. This event was a transfer of 137 contract(s) at a $195.00 strike. The total cost received by the writing party (or parties) was $25.8K, with a price of $189.0 per contract. There were 5038 open contracts at this strike prior to today, and today 319 contract(s) were bought and sold. 
• Regarding COR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>), we observe a put option sweep with neutral sentiment. It expires in 23 day(s) on June 20, 2025. Parties traded 135 contract(s) at a $280.00 strike. This particular put needed to be split into 27 different trades to become filled. The total cost received by the writing party (or parties) was $36.4K, with a price of $270.0 per contract. There were 762 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ABBV

AMGN

GILD

MRNA

REGN

VEEV

10 Health Care Stocks Whale Activity In Today's Session

Benzinga examined the prospects for<a href="http://www.benzinga.com/trading-ideas" target="_blank" rel="noreferrer noopener"> many investors' favorite stocks</a> over the last week — here's a look at some of our top stories.
U.S. markets experienced heightened volatility this week as President Donald Trump intensified trade tensions by threatening a 25% tariff on foreign-made Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) products and announcing a 50% tariff on European Union imports starting June 1. These announcements led to a decline in major indices, with the S&amp;P 500 falling 0.7%, the Dow Jones dropping 0.6%, and the Nasdaq decreasing by 1%. Apple shares were particularly affected, losing 3% in value.
Investor concerns over the U.S. fiscal outlook grew as the 30-year Treasury yield briefly surpassed 5.15%, reflecting apprehensions about rising deficits and debt sustainability. A weak 20-year Treasury auction further exacerbated these fears, indicating diminished demand for long-term U.S. debt.
Looking ahead, market participants are closely monitoring upcoming U.S.-China trade negotiations and potential adjustments to existing tariffs. The Federal Reserve's stance on interest rates remains a focal point, especially as real borrowing costs rise, tightening broader financial conditions. Additionally, corporate earnings reports and economic indicators will continue to influence market dynamics in the coming weeks.
Benzinga provides daily reports on the stocks most popular with investors. Here are a few of this past week's most bullish and bearish posts that are worth another look.

The Bulls
<a href="https://www.benzinga.com/trading-ideas/technicals/25/05/45544614/google-could-smart-glasses-smart-speech-spark-the-stocks-next-big-leap">"Google: Could smart glasses, speech spark the stock's next big leap?"</a>, by Surbhi Jain, reports that Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) is gaining investor attention as its partnership with Warby Parker to develop AI-powered smart glasses and advancements in speech recognition technology signal a potential new growth narrative beyond search.
<a href="https://www.benzinga.com/government/regulations/25/05/45574763/goldman-sachs-defense-stock-golden-dome">"Goldman Sachs: Golden Dome is big win for this defense stock"</a>, by Piero Cingari, reports that Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) analyst Noah Poponak reiterated a Buy rating on L3Harris Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>), highlighting its potential to secure billions in contracts from the Trump administration's $175 billion "Golden Dome" missile defense initiative.
<a href="https://www.benzinga.com/trading-ideas/movers/25/05/45531583/amd-nvidia-shares-jump-after-musk-highlights-xais-gpu-needs-we-expect-to-still-buy-a-lot">"AMD, Nvidia shares jump after Musk highlights xAI's GPU needs: ‘We expect to still buy a lot'"</a>, by Adam Eckert, reports that Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) and NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares rose after Elon Musk stated that Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and xAI plan to purchase "a lot" of GPUs from both companies to support AI initiatives like robotaxis and the Optimus robot.
For additional bullish calls of the past week, check out the following:
<a href="https://www.benzinga.com/trading-ideas/movers/25/05/45541780/d-wave-quantum-stock-extends-rally-as-momentum-builds-following-launch-of-new-quantum-system">D-Wave Quantum Stock Extends Rally As Momentum Builds Following Launch Of New Quantum System</a>
<a href="https://www.benzinga.com/25/05/45517783/magnificent-7-stun-the-street-with-the-best-earnings-beat-since-2021">Magnificent 7 Stun The Street With Best Earnings Beat Since 2021</a>
<a href="https://www.benzinga.com/25/05/45540768/medtronic-beats-q4-forecasts-hikes-dividend-plans-diabetes-spinoff">Medtronic Beats Q4 Forecasts, Hikes Dividend, Plans Diabetes Spinoff</a>

The Bears
<a href="https://www.benzinga.com/news/legal/25/05/45568107/solar-energy-stocks-drop-as-house-approves-major-rollback-of-climate-incentives">"Solar energy stocks drop as House approves major rollback of climate incentives"</a>, by Erica Kollmann, reports that Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) shares fell after the House passed President Trump's "One Big, Beautiful Bill," which rolls back key climate incentives, leaving the solar industry facing uncertainty as the bill moves to the Senate.
<a href="https://www.benzinga.com/25/05/45540759/target-stock-slips-as-q1-earnings-miss-estimates-fy2025-outlook-cut-amid-slowing-sales">"Target stock slips as Q1 earnings miss estimates, FY2025 outlook cut amid slowing sales"</a>, by Nabaparna Bhattacharya, reports that Target Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) shares fell after the company missed Q1 earnings expectations and lowered its FY2025 outlook, citing a 3.8% drop in comparable sales driven by tariffs, weakened consumer sentiment, and backlash from scaling back diversity, equity, and inclusion initiatives.
<a href="https://www.benzinga.com/news/rumors/25/05/45555558/wolfspeed-stock-plunges-59-on-bankruptcy-fears-options-traders-cash-in">"Wolfspeed stock plunges 59% on bankruptcy fears: Options traders cash in"</a>, by Erica Kollmann, reports that Wolfspeed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) shares plummeted 59% to $1.28 after reports emerged that the company is preparing to file for Chapter 11 bankruptcy, with options traders profiting from heavy put activity ahead of the news.
For more bearish takes, be sure to see these posts:
<a href="https://www.benzinga.com/government/regulations/25/05/45554854/health-care-stocks-like-unitedhealth-cvs-tank-on-wednesday-heres-why">Health Care Stocks Like UnitedHealth, CVS Tank On Wednesday: Here's Why</a>
<a href="https://www.benzinga.com/25/05/45567780/hims-hers-health-stock-is-tumbling-thursday-whats-happening">Hims &amp; Hers Health Stock Is Tumbling Thursday: What's Happening?</a>
<a href="https://www.benzinga.com/markets/equities/25/05/45532892/legendary-investor-jeremy-grantham-warns-of-50-stock-market-crash">Legendary Investor Jeremy Grantham Warns Of 50% Stock Market Crash</a>

Keep up with all the latest breaking news and trading ideas by following <a href="https://twitter.com/Benzinga" target="_blank" rel="noreferrer noopener">Benzinga</a><a href="http://twitter.com/Benzinga" target="_blank" rel="noreferrer noopener"> on X</a>.
Image created using artificial intelligence via Midjourney.

Markets

AAPL

GOOGL

Hims & Hers Health, Inc. Class A Common Stock

HIMS

NVDA

QBTS

TSLA

WOLF

Benzinga Bulls And Bears: Alphabet, L3Harris, Target — And Latest Tariff News Roils Markets

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/23/25</td>
<td>$300.00</td>
<td>$25.7K</td>
<td>6.4K</td>
<td>7.0K</td>
</tr>
<tr>
<td>MDT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/27/25</td>
<td>$76.00</td>
<td>$244.0K</td>
<td>10</td>
<td>4.0K</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$1000.00</td>
<td>$25.6K</td>
<td>361</td>
<td>274</td>
</tr>
<tr>
<td>SYK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$400.00</td>
<td>$52.8K</td>
<td>46</td>
<td>15</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/18/26</td>
<td>$450.00</td>
<td>$30.4K</td>
<td>93</td>
<td>6</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option trade that happens to be neutral, expiring in 1 day(s) on May 23, 2025. This event was a transfer of 60 contract(s) at a $300.00 strike. The total cost received by the writing party (or parties) was $25.7K, with a price of $429.0 per contract. There were 6422 open contracts at this strike prior to today, and today 7074 contract(s) were bought and sold. 
• For MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we notice a put option trade that happens to be bullish, expiring in 36 day(s) on June 27, 2025. This event was a transfer of 4000 contract(s) at a $76.00 strike. The total cost received by the writing party (or parties) was $244.0K, with a price of $61.0 per contract. There were 10 open contracts at this strike prior to today, and today 4000 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option sweep with bearish sentiment. It expires in 85 day(s) on August 15, 2025. Parties traded 54 contract(s) at a $1000.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $25.6K, with a price of $475.0 per contract. There were 361 open contracts at this strike prior to today, and today 274 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a put option sweep that happens to be bullish, expiring in 392 day(s) on June 18, 2026. This event was a transfer of 12 contract(s) at a $400.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $52.8K, with a price of $4400.0 per contract. There were 46 open contracts at this strike prior to today, and today 15 contract(s) were bought and sold. 
• For VRTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), we notice a put option trade that happens to be neutral, expiring in 392 day(s) on June 18, 2026. This event was a transfer of 5 contract(s) at a $450.00 strike. The total cost received by the writing party (or parties) was $30.4K, with a price of $6080.0 per contract. There were 93 open contracts at this strike prior to today, and today 6 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VRTX

5 Health Care Stocks Whale Activity In Today's Session

Mizuho analyst Anthony Petrone maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Outperform and lowers the price target from $100 to $98.

Price Target

Mizuho Maintains Outperform on Medtronic, Lowers Price Target to $98

RBC Capital analyst Shagun Singh maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Outperform and lowers the price target from $105 to $101.

RBC Capital Maintains Outperform on Medtronic, Lowers Price Target to $101

Baird analyst David Rescott maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Neutral and lowers the price target from $94 to $92.

Baird Maintains Neutral on Medtronic, Lowers Price Target to $92

U.S. equities trading was mixed on Wednesday, with major indices showing limited movement by midday as investors remained cautious amid renewed concerns over fiscal policy, which pressured Treasury <a href="https://www.benzinga.com/government/regulations/25/05/45540541/5-treasury-yields-are-back-and-so-are-painful-mortgage-rates">bonds and the dollar.</a>
The S&amp;P 500 hovered near 5,930, little changed on the day, while the Dow Jones Industrial Average slipped 0.7% amid weakness in blue-chip stocks. In contrast, the Nasdaq 100 advanced 0.5%, led by a 4.6% rally in Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>), which extended gains following its annual I/O developer conference.
Google unveiled a series of AI initiatives, highlighting that its Gemini assistant now boasts over 400 million monthly active users and delivers AI Overviews to more than 1.5 billion people. The company also touted Gemini 2.5 Pro's <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45548615/alphabet-well-positioned-for-google-search-dominance-analyst-says-can-navigate-the-shift-to-ai-search">performance leadership in industry benchmark</a>s.
Bond markets faced renewed selling pressure, with the 30-year Treasury yield surging to 5.02% — the highest in nearly two months — as traders digested the potential fiscal implications of President Donald Trump&#8216;s proposed "One Big Beautiful Bill," which economists say could further worsen the U.S. deficit outlook.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) stole the spotlight, surging past its previous record to hit an intraday high of $109,500, buoyed by news that JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) will allow clients to buy Bitcoin, though without offering custody services.
In commodities, oil prices eased 0.6% to $61.50 per barrel after an overnight spike triggered by unconfirmed reports of an Israeli strike on Iranian nuclear facilities. Gold rose 0.5% to $3,310 per ounce, marking its highest level since May 11.
<h1 class="wp-block-heading">Wednesday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Major Indices </td>
<td>Price</td>
<td>1-day % chg.</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,474.58</td>
<td>0.5%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,936.07</td>
<td>-0.1%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,379.01</td>
<td>-0.7%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,084.27</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:40 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul class="wp-block-list">
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) inched 0.2% down to $591.96.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) fell 0.7% to $423.84.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 0.4% to $522.58.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) sunk 1% to $207.08.</li>
<li>The&nbsp;Communication Services&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>) outperformed, up 0.6%; the&nbsp;Health Care&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) lagged, down 1.2%.</li>
</ul>
<h1 class="wp-block-heading">Wednesday&#8217;s Stock Movers</h1>
<ul class="wp-block-list">
<li>Keysight Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEYS#NYSE">KEYS</a>) rose 3.3% in reaction to earnings. </li>
<li>Other stocks reacting to earnings included TJX Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>), down 2.33; Lowe&#8217;s Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>), down 1.23%; Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), down 0.93%; Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>), down 4.12%; VF Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>), down 12.04%, FLEX LNG Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLNG#NYSE">FLNG</a>), down 7.27%.</li>
<li>Stocks slated to report earnings after the close include Urban Outfitters, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>), Zoom Video Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>), Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) and Domo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOMO#NASDAQ">DOMO</a>).</li>
</ul>
Read Now:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45548192/tesla-enters-its-most-bullish-window-this-seasonal-trade-delivered-24-average-gain-over-10-years">Tesla Enters Its Most Bullish Window: This Seasonal Trade Delivered 24% Average Gain Over 10 Years</a> Photo Courtesy: Antonio Gravante via Shutterstock </li>
</ul>

Equities

Macro Economic Events

Sector ETFs

Broad U.S. Equity ETFs

Econ #s

Economics

Federal Reserve

Tech

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

DOMO

FLNG

GOOG

KEYS

SNOW

URBN

Select Sector SPDR-Consumer Discretionary

Wall Street Stalls As Yields Rise, Bitcoin Breaks Records Above $109,000: What's Driving Markets Wednesday?

Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) reported fourth-quarter 2025 sales of $8.93 billion, beating the <a href="https://www.benzinga.com/pressreleases/25/05/n45538067/medtronic-reports-strong-finish-to-its-fiscal-year-with-its-fourth-quarter-financial-results-annou" target="_blank" rel="noreferrer noopener">consensus of $8.82 billion</a>.
The medical device maker reported:
<ul class="wp-block-list">
<li>Adjusted EPS of $1.62, beating the consensus of $1.58.</li>
<li>A year-over-year revenue increase of 3.9% <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">and 5.4% Y/Y organically</a>.</li>
<li>Cardiovascular segment revenue reaching $3.34 billion, up 6.6% year over year as reported, and increased 7.8% Y/Y organically.</li>
<li>An increase in low-double-digit in CRHF, high-single-digit in SH&amp;A, and low-single-digit in CPV (all on an organic basis).</li>
<li>Neuroscience revenues of $2.62 billion rose 2.9% Y/Y as reported. They rose 3.7% Y/Y organically, aided by an increase in low-double-digit in Neuromodulation and mid-single-digit in CST, all on an organic basis.</li>
<li>Medical Surgical&nbsp;revenue of&nbsp;$2.21 billion increased by&nbsp;0.6% Y/Y&nbsp;as reported and by&nbsp;2.0%&nbsp;Y/Y organically, with a low-single-digit organic growth in both SE and ACM segments.</li>
<li>Diabetes revenue of&nbsp;$728 million increased by&nbsp;10.4% Y/Y, as reported, and by&nbsp;12.0%&nbsp;Y/Y organically.</li>
</ul>
Dividend Increase: Effective May 20, the company&#8217;s board approved an increase in cash dividend per share by 1.4% to 71 cents for the first quarter of fiscal year 2026
The dividend is payable on&nbsp;July 11, 2025, to shareholders of record as of&nbsp;June 27, 2025.
Guidance:&nbsp;Medtronic expects its fiscal year 2026 organic <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">revenue&nbsp;growth&nbsp;guidance&nbsp;of&nbsp;5%</a>.
If recent foreign currency exchange rates hold, FY26 revenue growth would be around&nbsp;&nbsp;4.8% to 5.1% on a reported basis.
Medtronic expects 2025 adjusted EPS of&nbsp;$5.50-$5.60&nbsp;versus consensus of&nbsp;$5.83.
Diabetes Business Separation: Medtronic disclosed its intention to separate its Diabetes <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45538032/medtronic-announces-intent-to-separate-diabetes-business" rel="noreferrer noopener">business into a new standalone company</a>.
This move aims to create a more focused entity with a streamlined portfolio concentrated on high-margin growth markets.
The separation, expected within 18 months, will occur through capital markets transactions, with an initial public offering (IPO) followed by a split-off as the preferred method.
Upon separation, Medtronic anticipates an immediate improvement of approximately 50 basis points in adjusted gross margin, 100 basis points in adjusted operating margins, and an immediate accretion to adjusted EPS.
The separation is also expected to allow Medtronic to retire outstanding shares without impacting cash, leading to further EPS accretion and a reduced dividend liability.
Investors can gain exposure to the stock via Madison ETFs Trust Madison Covered Call ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVRD#NYSE">CVRD</a>) and Absolute Select Value ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABEQ#NYSE">ABEQ</a>).
Price Action:&nbsp;MDT stock is down 0.14% at $86.25 premarket at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/03/44451449/china-courts-apple-pfizer-eli-lilly-amid-us-pressure-vice-premier-says-beijing-will-continue-to-improve-the-business-environment" target="_blank" rel="noreferrer noopener">China Courts Apple, Pfizer, Eli Lilly Amid US Pressure, Vice Premier Says Beijing &#8216;Will Continue To Improve The Business Environment&#8217;</a></li>
</ul>
Image: Shutterstock

Earnings

Guidance

Dividends

ABEQ

CVRD

Medtronic Beats Q4 Forecasts, Hikes Dividend, Plans Diabetes Spinoff

Guidance The company today issued its fiscal year 2026 (FY26) revenue growth and EPS guidance.
The company is guiding to FY26 organic revenue growth of approximately 5%. The organic revenue growth guidance excludes the impact of foreign currency exchange and revenue reported as Other. Including Other revenue and the impact of foreign currency exchange, if recent foreign currency exchange rates hold, FY26 revenue growth on a reported basis would be in the range of 4.8% to 5.1%.
Excluding the potential impacts from increased tariffs, Medtronic expects FY26 diluted non-GAAP EPS growth to be approximately 4%. This includes an expectation for non-GAAP operating profit to grow faster than organic revenue, partially offset by increased interest and tax expense. Including a potential impact from tariffs as detailed in the company's earnings presentation, Medtronic is guiding FY26 diluted non-GAAP EPS in the range of $5.50 to $5.60. The lower end of the EPS range assumes that the bilateral US/China tariffs resume at the higher rates following the 90 day pause, while the higher end of the EPS range assumes that the bilateral US/China tariffs currently in effect during the pause remain in place through fiscal year 2026.
"Our fiscal 2026 guidance reflects increasing revenue growth contribution from our key growth drivers, and increased investment to support their growth, leading to leveraged operating profit growth pre-tariffs. In addition, the team has rallied to identify opportunities to offset a large portion of tariffs, and we have high confidence in our ability to execute additional mitigation efforts," said Thierry Piéton, Medtronic chief financial officer, who joined the company on March 3, 2025. "This is an exciting time to join Medtronic. I am energized by the opportunities for durable growth and value creation ahead of us."

Medtronic Sees FY2026 Adj EPS $5.50-$5.60 Vs $5.83 Est., Sees 5% Organic Revenue Growth

Dividend Increase The company today announced that effective May 20, 2025, the Medtronic board of directors approved an increase in Medtronic's cash dividend for the first quarter of fiscal year 2026, raising the quarterly amount to $0.71 per ordinary share. This would translate into an annual amount of $2.84 per ordinary share. Today's announcement marks the 48th consecutive year of an increase in the dividend payment. The dividend is payable on July 11, 2025, to shareholders of record at the close of business on June 27, 2025.

Medtronic Boosts Quarterly Dividend By 1.4% To $0.71, Payable July 11

Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) reported quarterly earnings of $1.62 per share which beat the analyst consensus estimate of $1.58 by 2.53 percent. This is a 10.96 percent increase over earnings of $1.46 per share from the same period last year. The company reported quarterly sales of $8.93 billion which beat the analyst consensus estimate of $8.82 billion by 1.17 percent. This is a 3.94 percent increase over sales of $8.59 billion the same period last year.

Earnings Beats

Medtronic Q4 Adj. EPS $1.62 Beats $1.58 Estimate, Sales $8.93B Beat $8.82B Estimate

Medtronic Announced Its Intent To Separate Its Diabetes Business Into A New Standalone Company

<h3>Companies Reporting Before The Bell</h3>
• MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) is likely to report quarterly loss at $0.66 per share on revenue of $5.20 million. 
• Canada Goose Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOOS#NYSE">GOOS</a>) is expected to report quarterly earnings at $0.16 per share on revenue of $262.86 million. 
• Ucloudlink Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCL#NASDAQ">UCL</a>) is projected to report quarterly loss at $0.04 per share on revenue of $18.20 million. 
• iQIYI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IQ#NASDAQ">IQ</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $973.69 million. 
• TJX Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>) is estimated to report quarterly earnings at $0.91 per share on revenue of $13.03 billion. 
• Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) is expected to report quarterly earnings at $1.58 per share on revenue of $8.83 billion. 
• Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) is likely to report quarterly earnings at $1.65 per share on revenue of $24.35 billion. 
• Lowe's Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) is likely to report quarterly earnings at $2.88 per share on revenue of $20.97 billion. 
• Baidu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) is estimated to report quarterly earnings at $1.34 per share on revenue of $4.30 billion. 
• Full Truck Alliance Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YMM#NYSE">YMM</a>) is estimated to report quarterly earnings at $0.16 per share on revenue of $366.75 million. 
• CMB.Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMBT#NYSE">CMBT</a>) is projected to report quarterly earnings at $0.28 per share on revenue of $224.00 million. 
• Golden Ocean Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOGL#NASDAQ">GOGL</a>) is projected to report quarterly loss at $0.15 per share on revenue of $106.48 million. 
• Wix.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) is projected to report quarterly earnings at $1.66 per share on revenue of $471.83 million. 
• Flex LNG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLNG#NYSE">FLNG</a>) is expected to report quarterly earnings at $0.44 per share on revenue of $88.17 million. 
• Cool Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLCO#NYSE">CLCO</a>) is estimated to report earnings for its first quarter. 
• Dycom Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DY#NYSE">DY</a>) is projected to report quarterly earnings at $1.62 per share on revenue of $1.19 billion. 
• Super Hi International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HDL#NASDAQ">HDL</a>) is likely to report earnings for its first quarter. 
• Evogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) is projected to report quarterly loss at $0.73 per share on revenue of $4.00 million. 
• WeRide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRD#NASDAQ">WRD</a>) is likely to report earnings for its first quarter. 
• Baozun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZUN#NASDAQ">BZUN</a>) is projected to report earnings for its first quarter. 
• XPeng (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) is likely to report earnings for its first quarter. 
• VF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) is estimated to report quarterly loss at $0.14 per share on revenue of $2.17 billion. 
• Weibo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WB#NASDAQ">WB</a>) is likely to report quarterly earnings at $0.38 per share on revenue of $394.21 million. 
<h3>Companies Reporting After The Bell</h3>
• LiveRamp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RAMP#NYSE">RAMP</a>) is projected to report quarterly earnings at $0.28 per share on revenue of $185.41 million. 
• Banco BBVA Argentina (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAR#NYSE">BBAR</a>) is projected to report quarterly earnings at $0.47 per share on revenue of $708.59 million. 
• Zoom Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) is projected to report quarterly earnings at $1.31 per share on revenue of $1.17 billion. 
• Urban Outfitters (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) is expected to report quarterly earnings at $0.82 per share on revenue of $1.29 billion. 
• American Superconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMSC#NASDAQ">AMSC</a>) is likely to report quarterly earnings at $0.10 per share on revenue of $60.27 million. 
• LexinFintech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LX#NASDAQ">LX</a>) is likely to report earnings for its first quarter. 
• Domo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOMO#NASDAQ">DOMO</a>) is likely to report quarterly loss at $0.19 per share on revenue of $77.75 million. 
• ClearSign Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLIR#NASDAQ">CLIR</a>) is projected to report earnings for its first quarter. 
• Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) is projected to report quarterly earnings at $0.21 per share on revenue of $1.01 billion. 
• EnerSys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENS#NYSE">ENS</a>) is projected to report quarterly earnings at $2.55 per share on revenue of $1.02 billion. 
• Borr Drilling (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BORR#NYSE">BORR</a>) is likely to report quarterly loss at $0.03 per share on revenue of $231.17 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMSC

BBAR

BIDU

BORR

BZUN

CLCO

CLIR

CMBT

EVGN

GOGL

GOOS

MDWD

RAMP

XPEV

Earnings Scheduled For May 21, 2025

Press Releases

Medtronic Expand URO U.S. clinical trial meets safety and effectiveness primary endpoints for Hugo™ robotic-assisted surgery system

Medtronic Affera™ pulsed field ablation technologies continue to demonstrate promising evidence for atrial fibrillation patients

New survey: 1 in 3 women have not talked to their doctor about heart health, the #1 killer of women

Medtronic to announce financial results for its fourth quarter and full fiscal year 2025

Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

Medtronic announces intent to separate Diabetes business

Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase

Medtronic chairman and CEO Geoff Martha to speak at Bernstein's Strategic Decisions Conference

Small Cap

AI in Healthcare Just Crossed a Tipping Point. Investors Are Watching These Names

Medtronic announces MiniMed as name for planned New Diabetes Company

AVAI

BFLY

OBIO

ORCL

RXRX

Abbott Laboratories

Baxter Intl

Becton, Dickinson and Company Common Stock

Becton Dickinson

Boston Scientific Corporation Common Stock

Boston Scientific

DexCom

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

Hologic

IDEXX Laboratories

iRhythm Technologies, Inc. - Common Stock

iRhythm Technologies

Intuitive Surgical

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Penumbra

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips

Insulet

ResMed

Smith & Nephew

Steris

Stryker

Teleflex

TransMedics Group

Zimmer Biomet Holdings, Inc. Common Stock

Zimmer Biomet Holdings

Mizuho

RBC Capital

Baird

Truist Securities

Citigroup

Screenshot 2024-10-03 at 5.30.47 PM

DXCM

GCTK

SENS

Expanding Continuous Glucose Monitoring Options: How Glucotrack Is Helping Usher In The Next Generation Of Diabetes Care Technology

Screenshot 2024-09-30 at 5.38.54 PM

Movers & Shakers

COSM

Nestle Sponsored representing Registered Shares Series B

NSRGY

VTRS

How Cosmos Health&#39;s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Comments

Medtronic

空売り

Medtronic (NYSE:MDT) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル